GET DAILY SIGNALSAcrivon Therapeutics (ACRV): Analyst Targets Point to +540% Upside to $11
Key Takeaways
- The central $11 price target is the arithmetic mean of seven current, individually attributed analyst price targets for Acrivon Therapeutics (ACRV), a clinical-stage precision oncology company.
- With shares trading near $1.72, reaching $11 implies roughly 540% upside, a very large move relative to the recent price.
- Analyst targets span a wide $7 to $19 range, reflecting substantial disagreement about the value of upcoming clinical data despite a uniformly bullish rating mix.
- The strongest support comes from the lead ACR-368 Phase 2b program in endometrial cancer and the earlier-stage ACR-2316 candidate, while the biggest risks are clinical-trial outcomes, cash burn, and small-cap volatility.
- For more context, review the Major News, Today's Price Move, Forecast, and Earnings pages.
What the Analysts Are Saying
Acrivon Therapeutics (ACRV) carries a current, attributed analyst price-target set spanning roughly $7 to $19. Recent, verifiable targets include Maxim Group at $7, Oppenheimer and Piper Sandler each at $8, Gabelli at $8, Citizens JMP at $13, Jefferies at $14, and H.C. Wainwright at $19. The arithmetic mean of these seven targets is approximately $11, which is the central target used here. Because all current ratings are Buy, Outperform, or Overweight equivalents, the "consensus" is bullish in tone, but the $7-to-$19 spread shows analysts do not agree on magnitude.
Notable recent changes include Piper Sandler raising its target from $6 to $8 (January 2026), Oppenheimer assuming coverage with an Outperform rating and $8 target (June 2026), and Gabelli initiating at Buy with $8. The wide gap reflects differing views on how much credit to give the ACR-368 Phase 2b interim readout in serous endometrial cancer and the ACR-2316 dose-expansion data expected in 2027. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Where ACRV Stands Today
Shares of ACRV have recently traded near $1.72, within a 52-week range of roughly $1.27 to $3.56, with a market capitalization near $74 million. Moving to $11 would require upside of about 540%, a very large move by any standard and far above the stock's prior 52-week high. For a pre-revenue biotech, such a path is almost entirely dependent on clinical data, not on near-term earnings.
Acrivon has no product revenue and posts quarterly GAAP net losses in the high-teens of millions of dollars. The investment case therefore rests on its AP3 (Acrivon Predictive Precision Proteomics) platform and its two lead clinical assets. A positive interim analysis from ACR-368 — a CHK1/CHK2 inhibitor being studied in Phase 2b serous endometrial cancer, both as monotherapy and in combination — would be the most direct catalyst for a sustained repricing. The company also benefits from a balance sheet where enterprise value is negative, indicating net cash that exceeds the market capitalization, which reduces near-term dilution risk relative to many peers.
What Could Support a Move Toward the Target
- ACR-368 interim data: An interim analysis of the Phase 2b serous endometrial cancer study is anticipated in the second half of 2026; response rates meaningfully above standard of care could support a registrational path.
- ACR-2316: Early efficacy and a clean safety profile, now advancing into randomized dose expansion, provide a second, independent value driver.
- Platform breadth: The AP3 engine, including a CDK11 program moving toward an investigational new drug (IND) filing, underpins a multi-asset story.
- Net cash position: Negative enterprise value implies cash holdings above market value, giving the company runway to reach key readouts.
What Could Prevent the Target From Being Reached
- Clinical risk: ACR-368 data could miss efficacy thresholds, erasing the primary driver of the bull case.
- Cash burn: Ongoing quarterly losses will eventually require additional capital, which can dilute existing shareholders.
- Valuation compression: Pre-revenue biotechs are highly sensitive to sector-wide risk appetite and interest-rate conditions.
- Wide target dispersion: The $7-to-$19 spread signals that even bulls disagree sharply on fair value, reflecting genuine uncertainty.
Technical Levels and Market Structure
On a technical basis, ACRV trades in the lower portion of its 52-week range of roughly $1.27 to $3.56. The $1.27 area marks a notable prior low and potential support zone, while the $3.56 level represents a major resistance from the stock's prior high. Because the $11 target sits well above any established trading range, there are no meaningful resistance levels between the current price and the target — the gap reflects clinical catalysts rather than technical structure.
Time Horizon and What Investors Should Monitor
Analyst price targets typically reflect a roughly 12-month research horizon, though individual analysts may differ. The most important near-term item is the ACR-368 Phase 2b interim analysis in serous endometrial cancer, expected in the second half of 2026, followed by ACR-2316 dose-expansion data targeted for 2027. Investors should also track quarterly cash position and burn, analyst target revisions after any data readout, and broader biotech-sector sentiment, which influences how aggressively pre-revenue names are valued. From what I see, these milestones will likely drive the next meaningful moves.
Monitoring with AI Tools
In my own workflow, I frequently rely on Tickeron’s AI Daily Buy/Sell Signals to track how names like ACRV are behaving amid shifting market conditions. The system generates Buy, Sell, or Hold signals based on technical behavior and AI-driven analysis, which helps me surface potential opportunities and monitor existing positions more efficiently than manual screening alone. It serves as a useful complement when evaluating clinical-stage names where catalysts can arrive quickly.
Final Assessment
Can Acrivon Therapeutics (ACRV) reach $11? The question hinges on binary clinical outcomes rather than steady execution. The $11 central target, derived from seven current analyst targets ranging from $7 to $19, implies roughly 540% upside from a price near $1.72 — a move that would require meaningfully positive ACR-368 Phase 2b data and continued progress on ACR-2316. A net cash balance and a uniformly bullish analyst base provide a foundation, but pre-revenue biotech investing carries outsized risk, and the wide target dispersion underscores that even supportive analysts disagree sharply on value. Investors should watch the ACR-368 interim readout and any subsequent analyst revisions as the key signposts.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
ACRV's RSI Oscillator climbs out of oversold territory
The RSI Oscillator for ACRV moved out of oversold territory on October 19, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 27 similar instances when the indicator left oversold territory. In 27 of the 27 cases the stock moved higher. This puts the odds of a move higher at 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 46 of 56 cases where ACRV's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 82%.
Following a +7.99% 3-day Advance, the price is estimated to grow further. Considering data from situations where ACRV advanced for three days, in 180 of 202 cases, the price rose further within the following month. The odds of a continued upward trend are 89%.
ACRV may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 05, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ACRV as a result. In 62 of 73 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 85%.
The Moving Average Convergence Divergence Histogram (MACD) for ACRV turned negative on October 02, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 34 similar instances when the indicator turned negative. In 31 of the 34 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
ACRV moved below its 50-day moving average on October 06, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for ACRV crossed bearishly below the 50-day moving average on October 12, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 8 of 11 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 73%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ACRV declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.
The Aroon Indicator for ACRV entered a downward trend on October 27, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 40 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 46 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.860) is normal, around the industry mean (2.974). P/E Ratio (-0.926) is within average values for comparable stocks, (-0.899). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (135.903) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (439.237).
The Tickeron Price Growth Rating for this company is 61 (best 1 - 100 worst), indicating steady price growth. ACRV’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ACRV’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology
Advertisement